In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
CTS merges with the three Red Cross testing laboratories located in Charlotte, Portland and St. Loui...
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....